Abstract
Cachexia is often associated with severe loss of skeletal muscle mass and a reduced energy metabolism. The maintenance of muscle mass can be generally regarded as a simple balance between protein synthesis and protein degradation. Several evidences are available in the current literature favoring a model in which myofilaments are released from the sarcomere by the action of calciumactivated calpains followed by the degradation of the myofilaments by the ubiquitin proteasome system. The initiation of the protein breakdown machinery is regulated by several factors like inflammatory cytokines, angiotensin II, insulin / insulin like growth factor 1 and reactive oxygen species. These factors also have the capability to influence PGC-1alpha activity, thereby regulating mitochondrial energy production. All these molecular alterations regulating muscle mass and energy production in the skeletal muscle finally leads to a reduction in exercise capacity in cachexia.
Keywords: Ubiquitin-proteasome-system (UPS), muscle protein balance, exercise training, cachexia, mitochondria, inflammatory cytokines, reactive oxygen species, atrophy, insulin, myostatin
Current Pharmaceutical Design
Title: Muscle Metabolism and Exercise Capacity in Cachexia
Volume: 17 Issue: 35
Author(s): Volker Adams, Stefan D. Anker and Gerhard Schuler
Affiliation:
Keywords: Ubiquitin-proteasome-system (UPS), muscle protein balance, exercise training, cachexia, mitochondria, inflammatory cytokines, reactive oxygen species, atrophy, insulin, myostatin
Abstract: Cachexia is often associated with severe loss of skeletal muscle mass and a reduced energy metabolism. The maintenance of muscle mass can be generally regarded as a simple balance between protein synthesis and protein degradation. Several evidences are available in the current literature favoring a model in which myofilaments are released from the sarcomere by the action of calciumactivated calpains followed by the degradation of the myofilaments by the ubiquitin proteasome system. The initiation of the protein breakdown machinery is regulated by several factors like inflammatory cytokines, angiotensin II, insulin / insulin like growth factor 1 and reactive oxygen species. These factors also have the capability to influence PGC-1alpha activity, thereby regulating mitochondrial energy production. All these molecular alterations regulating muscle mass and energy production in the skeletal muscle finally leads to a reduction in exercise capacity in cachexia.
Export Options
About this article
Cite this article as:
Adams Volker, D. Anker Stefan and Schuler Gerhard, Muscle Metabolism and Exercise Capacity in Cachexia, Current Pharmaceutical Design 2011; 17 (35) . https://dx.doi.org/10.2174/138161211798357746
DOI https://dx.doi.org/10.2174/138161211798357746 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter
Current Pharmaceutical Design Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents S100A1: Structure, Function, and Therapeutic Potential
Current Chemical Biology Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Role of Estrogen Receptors and GPR30/GPER in Glucose Homeostasis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide
Current Medicinal Chemistry Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endophenotypes and Biological Markers of Schizophrenia: From Biological Signs of Illness to Novel Treatment Targets
Current Pharmaceutical Design Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Cross-Talk Between Adipose Tissue Health, Myocardial Metabolism and Vascular Function: The Adipose-Myocardial and Adipose-Vascular Axes
Current Pharmaceutical Design Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Cardiovascular & Hematological Agents in Medicinal Chemistry Passive Smoking and Coronary Heart Disease
Current Vascular Pharmacology T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology Usefulness of Magnetic Resonance Imaging in Cardiac and Enovascular Intervention
Current Medical Imaging The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy The Role of Trimetazidine After Acute Myocardial Infarction
Current Vascular Pharmacology